A cache of brain cancer biomedical data has been made freely available to researchers worldwide, say researchers at Georgetown Lombardi Comprehensive Cancer Center. The dataset, Repository for Molecular Brain Neoplasia Data, also known as REMBRANDT, hosted and supported by Georgetown, is one of only two such large collections in the country.
Almost one year after FDA approval of chimeric antigen receptor T-cell therapy for children with acute lymphoblastic leukemia, researchers at MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network published treatment guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology.
In the first such clinical trial in the United States, physician-scientists with the University of Maryland School of Medicine are investigating the use of MRI-guided focused ultrasound to open the blood-brain barrier. The trial will be conducted with patients undergoing brain cancer surgery at the University of Maryland Medical Center.
Researchers at UC Davis, Genentech, and Foundation Medicine are the first to show that a blood-based test to assess tumor mutational burden accurately identifies non-small cell lung cancer patients who could benefit from immunotherapies called checkpoint inhibitors.
Steven RosenbergCarl JuneJames AllisonSteven Rosenberg, Carl June and James Allison received the 2018 Albany Medical Center Prize in Medicine and Biomedical Research.
Karen Knudsen, enterprise director of the Sidney Kimmel Cancer Center–Jefferson Health, was elected vice president/president-elect of the Association of American Cancer Institutes' board of directors.
Cory Wiegert was named chief executive officer of CancerLinQ LLC, a non-profit subsidiary of the American Society of Clinical Oncology.
Moffitt Cancer Center's chief information security officer will join a group of experts charged with protecting and enhancing national cybersecurity.
Exact Sciences Corp. and Pfizer Inc. announced an agreement through 2021 to co-promote Cologuard, the only FDA-approved non-invasive stool DNA screening test for colorectal cancer. Pfizer will join the Exact Sciences sales representatives in reaching both physicians and health systems and will also actively participate in extending and deepening the Cologuard marketing campaign.
MD Anderson Cancer Center and Accelerator Life Science Partners announced the launch of Magnolia Neurosciences Corp., a company developing a new class of neuroprotective medicines, with $31 million in Series A funding. The company will develop novel therapeutics based on discoveries made by researchers in MD Anderson's Therapeutics Discovery division, including the Institute for Applied Cancer Science and the Neurodegeneration Consortium.
